UPDATE – 2022 Canadian Urological Association recommendations on prostate cancer screening and early diagnosis: Endorsement of the 2021 Cancer Care Ontario guidelines on prostate multiparametric magnetic resonance imaging – Summary of changes

Auteurs-es

  • Ross J. Mason Department of Urology, Dalhousie University
  • Karim Marzouk Division of Urology, Memorial Sloan Kettering Cancer Centre
  • Antonio Finelli Division of Urology, University of Toronto
  • Fred Saad Department of Surgery (Urology), University of Montreal
  • Alan I. So Department of Urologic Sciences, University of British Columbia
  • Phillipe D. Violette Department of Surgery, Western University; and Departments of Surgery and Health Research Methods, Evidence, and Impact, McMaster University
  • Rodney H. Breau Division of Urology, University of Ottawa
  • Ricardo A. Rendon Department of Urology, Dalhousie University

DOI :

https://doi.org/10.5489/cuaj.7832

Mots-clés :

prostate cancer screening, PSA, mpMRI, imaging

Téléchargements

Les données relatives au téléchargement ne sont pas encore disponibles.

Téléchargements

Publié-e

2022-03-31

Comment citer

Mason, R. J. ., Marzouk, K. ., Finelli, A. ., Saad, F., So, A. I., Violette, P. D. ., … Rendon, R. A. . (2022). UPDATE – 2022 Canadian Urological Association recommendations on prostate cancer screening and early diagnosis: Endorsement of the 2021 Cancer Care Ontario guidelines on prostate multiparametric magnetic resonance imaging – Summary of changes. Canadian Urological Association Journal, 16(4). https://doi.org/10.5489/cuaj.7832

Numéro

Rubrique

CUA Guideline